The WHO has urged China to increase adoption of mRNA vaccines, given their high efficacy against variant strains.
mRNA-1345 demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults
Products offered on a not-for-profit basis to the 45 lower-income countries now include the full portfolio for which Pfizer has global rights.
The company has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals
The Institute will focus on increasing preparedness and laboratory capabilities for identification of novel and unknown zoonotic agents
If approved, TAK-003 has the potential to become an important dengue prevention option for healthcare providers
The product is expected to be launched by Q4 FY23.
Program will fight the rising incidence of antimicrobial (drug) resistance and improve patient outcomes
Micafungin for Injection had annual sales of US $99 million in the United States according to IQVIA data
Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
Subscribe To Our Newsletter & Stay Updated
